ADG106

Overview

ADG106 is an agonist monoclonal antibody targeting 4-1BB (TNFRSF9), a T-cell co-stimulatory receptor. It is designed to enhance anti-tumor T-cell activity. ADG106 was in phase I investigation in solid tumors including nasopharyngeal carcinoma (NPC) at the time of this review; no significant NPC-specific activity has been reported.

Evidence in the corpus

Cited among investigational T-cell co-stimulatory agonists (4-1BB) tested in phase I in NPC; no significant NPC activity reported to date PMID:24952746.

Resistance mechanisms

Cancer types (linked)

Sources

This page was processed by entity-page-writer on 2026-05-11.